Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Ownership  |  Insiders

Stock Quote Today & Recent News Carisma Therapeutics Inc CARM

Carisma Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on macrophage engineering to develop transformative therapies to treat serious diseases including liver fibrosis and cancer. The Company seeks to apply the ability to engineer macrophages and monocytes, either in vivo or ex vivo. Its proprietary chimeric antigen receptor macrophages(CAR-M) platform uses CARs to... see more

Current News (GREY:CARM)

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, HSON, TTNP on Behalf of Shareholders

GlobeNewswire July 26, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates NVEE, CARM, HLGN on Behalf of Shareholders

PR Newswire July 16, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Launches Legal Inquiry for the Merger: TURN, HLGN, CARM, and GNTY

PR Newswire July 14, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates BASE, CARM, ENZB on Behalf of Shareholders

GlobeNewswire July 5, 2025

$HAREHOLDER ALERT: The M&A Class Action Firm Investigates the Merger: CARM, GNTY, TSBX, and SAGE

PR Newswire July 3, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates GMS, BASE, CARM, ENZB on Behalf of Shareholders

PR Newswire July 1, 2025

$HAREHOLDER ALERT: Class Action Attorney Juan Monteverde Investigates the Merger of Carisma Therapeutics Inc. (NASDAQ: CARM)

GlobeNewswire June 30, 2025

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates CARM, ENZB, GNTY on Behalf of Shareholders

PR Newswire June 27, 2025

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Carisma Therapeutics Inc. (Nasdaq - CARM), Guaranty Bancshares, Inc. (NYSE - GNTY), MRC Global Inc. (NYSE - MRC), Turnstone Biologics Corp. (Nasdaq - TSBX)

GlobeNewswire June 27, 2025

Opinion & Analysis (GREY:CARM)

Cancer Fighter Sesen Bio Leaps 13% on FDA Decision

Streetwise Reports May 22, 2019

Bullboard Posts (GREY:CARM)

RE:SESEN / CARISMA

Well it looks like I am the only one here. Too bad. I try to get the  reason for its  UD$ 1.52 plus drop?? 
Torrequebrada - July 25, 2023

SESEN / CARISMA

we,ve been fleeced by SESEN and  now we,re realy get  SC.....ed by Carisma.  Man o Man it just never ends. What a bunch of...
Torrequebrada - March 10, 2023

RE:4 BIOTECH STOCKS FACING FDA REJECTION!

floatinketucky - January 24, 2022

sesn flying flamming turd

To catch is risk of splatter and burn.  The market know for sure. Just look to the chart. More pain cometh.  This song is...
floatinketucky - January 24, 2022

BIG VOLUME NEW LOWS... NOT THE DARLIN. THE MARKET KNOWS.

<< View Post To Watch Video >>
floatinketucky - January 24, 2022

SESN .... Volume is huge

sold into the strength Could re-load  Cheers 1
Iseneschal - October 20, 2021